leadf
logo-loader
ASX:MXC

MGC Pharmaceuticals Ltd

Receive alerts
Market:
ASX
Market Cap:
$39.38 m
Price
0.02 AUD
Change
4.35%
52 weeks high
0.04
52 weeks low
0.02

An EU pharmaceutical licensed company, MGC Pharmaceuticals Ltd (ASX: MXC) is an industry-leading, European biopharma company supplying GMP Phytocannabinoid derived medicines to patients globally.

Who We Help

MGC Pharmaceuticals is able to help diverse groups of people through the research and development of pharmaceutical products.

MGC Pharma’s primary purpose is to help our patients by delivering medicines that offer Phytocannabinoid based solutions to increase patients’ quality of life. MGC Pharma strives to engage with patients in order to understand their needs and issues. This helps ensure that our medications are accessible and of the highest quality.

(click here for more information)


We research

MGC has an ambitious international research and development agenda. Research and development projects include preclinical, clinical and botanical, focused at the intersection of phytocannabinoid-derived medicines and the pharmaceutical industry. The Company undertakes research, itself and in collaboration with research institutes or universities in three main locations: Australia, Slovenia and Malta (under construction).

The Company’s Clinical Advisory Team is responsible for leading three main research and development areas: Neurology, Oncology and Autoimmune.

(click here for more information)


What We Make

MGC Pharma operates in several different segments of the Phytocannabinoid-based medicines.

MGC Pharma applies high standards of QA and QC to different segments of the Phytomedicine industry, allowing us to meet and exceed Good Manufacturing Practice (GMP) and GACP protocols, globally. Our company operates three pioneering divisions.

(click here for more information)


Last updated 14th July 2020

ROBY ZOMER
CO-FOUNDER & MANAGING DIRECTO

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC’s position as a leader in research and development, as well as ensuring top performance from our global operations. His recent appointment to CEO follows successful implementation of MGC’s pipelines for Pharma in Australia and Slovenia, and indicates MGC’s commitment to scientific leadership.


BRETT MITCHELL
EXECUTIVE CHAIRMAN

Mr Mitchell is a corporate finance executive with over 20 years of experience in the finance and resources industries. He has been involved in the founding, financing and management of both private and publicly-listed resource companies and holds executive and non-executive directorship roles. Mr Mitchell holds a Bachelor of Economics from the University of Western Australia and is also a member of the Australian Institute of Company Directors (AICD).


NATIV SEGEV
FOUNDER, DIRECTOR

Previously CEO of a leading Medical Cannabis company with a large patient base, as well as over 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles. Founded MGC Pharmaceuticals to expand into the International markets and to raise the quality of, and access to Medicinal Phytocannabinoid products to patients worldwide.


DR. ROSS WALKER
DIRECTOR & HEAD OF ADVISORY BOARD

Dr Ross Walker is an eminent practicing cardiologist with over 35 years’ experience as a clinician. For the past 20 years, he has been focusing on preventative cardiology and is one of Australia’s leading preventative health experts. Considered one of the world’s best keynote speakers and life coaches, he is the author of seven best-selling books, a health presenter in the Australian Media, including regular appearances on the Nine Network’s ‘Today Show’ and ‘A Current Affair’, and Sky News, Switzer Business. He also has a weekly radio show on Sydney’s 2UE/ 4BC &2CC with other regular segments on 2UE, 6PR, 4BC and 3AW.


DR. STEPHEN B. PARKER
DIRECTOR & CHAIRMAN OF THE CORPORATE GOVERNANCE COMMITTEES

Stephen Parker is a seasoned executive with over thirty years’ experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier with Baring’s, Warburg’s and Apax Partners.  Stephen is currently Chairman of Sareum Holdings plc and a Non-Executive Director of Eternans Limited.  Stephen has a D.Phil. from Oxford University and an MBA from City University Business School.


Last updated 14th July 2020

UNITED KINGDOM

EUROPEAN CORPORATE HEADQUARTERS
Central Working Ecclestone Yards 25, Ecclestone Place, London SW1W 9NF

+61 8 6382 3390
info@mgcpharma.com.au


SLOVENIA

PHARMA EUROPEAN OPERATIONAL HEADQUARTERS
Emonska Cesta 81000 Ljubljana

+386 1 777 6570
info@mgcpharma.com.au


AUSTRALIA

PHARMA CORPORATE & FINANCIAL HEADQUARTERS
1202 Hay Street West Perth

+61 8 6382 3390
info@mgcpharma.com.au


CZECH REPUBLIC

BOTANICAL RESEARCH & DEVELOPMENT PANAX PHARMA S.R.O
Ve Smečkách 1258/6 110 00 Praha 1

+420 222 518 288
info@mgcpharma.com.au